Prognostic Factors in Patients with Malignant Pleural Mesothelioma

• Main Authors: Vyacheslav P. Kurchin, Vladimir V. Zharkov
• Format: Article
• Language: English
• Published: International Medical Research and Development Corporation 2015-03-01
• Series: International Journal of Biomedicine
• Subjects: malignant pleural mesothelioma; extrapleural pneumonectomy; intrapleural perfusion hyperthermo-chemotherapy; multimodality treatment.
• Online Access: http://ijbm.org/articles/Article5(1)_CR1.pdf

The aim of the present study was to examine the factors of prognosis in patients with malignant pleural mesothelioma (MPM) after combined and multimodality treatment, including the prognostic significance of preoperative intrapleural perfusion hyperthermo-chemotherapy (IPHC). Material and Methods: The study included 20 patients (11 men and 9 women) aged from 30 to 70 years (mean age 51.9±8.5 years) who underwent surgical treatment for MPM. The diagnosis of MPM was verified by immunohistochemical data. The patients were divided into two groups. Group 1 included 9 patients who underwent combined treatment that included the extrapleural pneumonectomy (EPP) and 4 courses of adjuvant chemotherapy. Group 2 included 11 patients who received multimodality treatment (IPHC, EPP, and 4 courses of adjuvant chemotherapy). All patients were followed prospectively at three-monthly intervals for the first year and six-monthly thereafter until the last time of contact or death. Statistical analysis was performed by using Kaplan-Meier method and the log-rank test. Cox-regression model was used for multivariate analysis. Results: Patient’s age over 60 years and the sarcomatoid type of the tumor can be regarded as prognostic factors for poor survival in patients with MPM who underwent EPP. Application of IPHC as a part of a multimodality treatment enhances the survivability of MPM patients.